As an upstream driver of mTOR pathway, Ccrk inhibition is sufficient to reverse the metabolic and oncogenic phenotypes in multiple NASH and HCC models. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatohepatitis.